Article Versions Notes

Gusakova M, Sharko F, Mamchur A, Boulygina E, Mochalova A, Bullikh A, Patrushev M. Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy. Biomedicines. 2025; 13(11):2592. https://doi.org/10.3390/biomedicines13112592

Gusakova, Mariia, Fedor Sharko, Aleksandra Mamchur, Eugenia Boulygina, Anastasia Mochalova, Artem Bullikh, and Maxim Patrushev. 2025. "Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy" Biomedicines 13, no. 11: 2592. https://doi.org/10.3390/biomedicines13112592

Gusakova, M., Sharko, F., Mamchur, A., Boulygina, E., Mochalova, A., Bullikh, A., & Patrushev, M. (2025). Mutations in CREBBP and EP300 HAT and Bromo Domains Drive Hypermutation and Predict Survival in GI Cancers Treated with Immunotherapy. Biomedicines, 13(11), 2592. https://doi.org/10.3390/biomedicines13112592